{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:12:27Z","timestamp":1791364347178,"version":"4.3.1"},"reference-count":28,"publisher":"American Society for Microbiology","issue":"19","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Virol"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>The immunogenicity and durability of genetic vaccines are influenced by the composition of gene inserts and choice of delivery vector. DNA vectors are a promising vaccine approach showing efficacy when combined in prime-boost regimens with recombinant protein or viral vectors, but they have shown limited comparative efficacy as a stand-alone platform in primates, due possibly to suboptimal gene expression or cell targeting. Here, regimens using DNA plasmids modified for optimal antigen expression and recombinant adenovirus (rAd) vectors, all encoding the glycoprotein (GP) gene from Angola Marburg virus (MARV), were compared for their ability to provide immune protection against lethal MARV Angola infection. Heterologous DNA-GP\/rAd5-GP prime-boost and single-modality rAd5-GP, as well as the DNA-GP-only vaccine, prevented death in all vaccinated subjects after challenge with a lethal dose of MARV Angola. The DNA\/DNA vaccine induced humoral responses comparable to those induced by a single inoculation with rAd5-GP, as well as CD4<jats:sup>+<\/jats:sup>and CD8<jats:sup>+<\/jats:sup>cellular immune responses, with skewing toward CD4<jats:sup>+<\/jats:sup>T-cell activity against MARV GP. Vaccine regimens containing rAd-GP, alone or as a boost, exhibited cellular responses with CD8<jats:sup>+<\/jats:sup>T-cell dominance. Across vaccine groups, CD8<jats:sup>+<\/jats:sup>T-cell subset dominance comprising cells exhibiting a tumor necrosis factor alpha (TNF-\u03b1) and gamma interferon (IFN-\u03b3) double-positive functional phenotype was associated with an absence or low frequency of clinical symptoms, suggesting that both the magnitude and functional phenotype of CD8<jats:sup>+<\/jats:sup>T cells may determine vaccine efficacy against infection by MARV Angola.<\/jats:p>","DOI":"10.1128\/jvi.00594-10","type":"journal-article","created":{"date-parts":[[2010,7,22]],"date-time":"2010-07-22T02:45:06Z","timestamp":1279766706000},"page":"10386-10394","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":70,"title":["Vector Choice Determines Immunogenicity and Potency of Genetic Vaccines against Angola Marburg Virus in Nonhuman Primates"],"prefix":"10.1128","volume":"84","author":[{"given":"Thomas W.","family":"Geisbert","sequence":"first","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702-5011"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bailey","sequence":"additional","affiliation":[{"name":"Biodefense Research Section"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan B.","family":"Geisbert","sequence":"additional","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702-5011"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement","family":"Asiedu","sequence":"additional","affiliation":[{"name":"Biodefense Research Section"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Roederer","sequence":"additional","affiliation":[{"name":"Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Grazia-Pau","sequence":"additional","affiliation":[{"name":"Crucell, Archimedesweg 4-6, 2333 CN Leiden, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Custers","sequence":"additional","affiliation":[{"name":"Crucell, Archimedesweg 4-6, 2333 CN Leiden, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Jahrling","sequence":"additional","affiliation":[{"name":"Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20817-7609"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap","family":"Goudsmit","sequence":"additional","affiliation":[{"name":"Crucell, Archimedesweg 4-6, 2333 CN Leiden, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Koup","sequence":"additional","affiliation":[{"name":"Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy J.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Biodefense Research Section"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.14.8828-8834.2005"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-4818"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20052246"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1592"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.9.5372"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/520608"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3780021"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1998.9367"},{"key":"e_1_3_2_10_2","first-page":"101","volume":"11","year":"1996","unstructured":"Johnson, E. D., B. K. Johnson, D. Silverstein, P. Tukei, T. W. Geisbert, A. N. Sanchez, and P. B. Jahrling. 1996. Characterization of a new Marburg virus isolated from a 1987 fatal case in Kenya. Arch. Virol. Suppl.11:101-114.","journal-title":"Arch. Virol. Suppl."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1258"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1970.tb45614.x"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2432"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.7.2.175"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(04)01103-X"},{"key":"e_1_3_2_16_2","unstructured":"Guide for the care and use of laboratory animals. 1996"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2006.04.007"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20062363"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(03)00362-1"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.10.6516-6522.2005"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.07.050"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri2274"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature01876"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2129"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/35046108"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00431-07"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.7.4.417"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00069-06"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.4049\/jimmunol.161.10.5594","volume":"161","year":"1998","unstructured":"Uchijima, M., A. Yoshida, T. Nagata, and Y. Koide. 1998. Optimization of codon usage of plasmid DNA vaccine is required for the effective MHC class I-restricted T cell responses against an intracellular bacterium. J. Immunol.161:5594-5599.","journal-title":"J. Immunol."}],"container-title":["Journal of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JVI.00594-10","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JVI.00594-10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T07:03:09Z","timestamp":1685689389000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JVI.00594-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":28,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1128\/JVI.00594-10"],"URL":"https:\/\/doi.org\/10.1128\/jvi.00594-10","relation":{},"ISSN":["0022-538X","1098-5514"],"issn-type":[{"value":"0022-538X","type":"print"},{"value":"1098-5514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"2010-03-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-07-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-10-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}